Findings

What do systematic reviews say?

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings: catgut implantation at acupoints plus antiepileptic drugs vs antiepileptic drugs alone

Nausea · people with epilepsy

Summary of findings: catgut implantation at acupoints plus… showed no clear difference in frequency of adverse effects ‐ nausea ( compared with antiepileptic drugs alone (low certainty).

1 finding from 1 review

Acupuncture for epilepsy 2014 · Cochrane Headline outcomes only
RR 0.33 [0.09, 1.17]
1 study · 120 participants
Low

Summary of findings: catgut implantation at acupoints plus antiepileptic drugs vs antiepileptic drugs alone

Frequency of adverse effects ‐ anorexia ( · people with epilepsy

Summary of findings: catgut implantation at acupoints plus… showed no clear difference in frequency of adverse effects ‐ anorexia ( compared with antiepileptic drugs alone (low certainty).

1 finding from 1 review

Acupuncture for epilepsy 2014 · Cochrane Headline outcomes only
RR 0.25 [0.06, 1.13]
1 study · 120 participants
Low

Summary of findings table ‐ Therapeutic exercise plus non‐surgical intervention vs non‐surgical treatment

Angle of trunk rotation · adolescents with idiopathic scoliosis

1 finding from 1 review

Therapeutic exercises for idiopathic scoliosis in adolescents 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Summary of findings table ‐ Therapeutic exercise plus non‐surgical intervention vs non‐surgical treatment

Subjective evaluation (SAQ General) – PSSE plus bracing vs bracing alone · adolescents with idiopathic scoliosis

1 finding from 1 review

Therapeutic exercises for idiopathic scoliosis in adolescents 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Summary of findings table ‐ Therapeutic exercise plus non‐surgical intervention vs non‐surgical treatment

Subjective evaluation (SRS‐22 Self‐Image) · adolescents with idiopathic scoliosis

1 finding from 1 review

Therapeutic exercises for idiopathic scoliosis in adolescents 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Summary of findings table ‐ Therapeutic exercise plus non‐surgical intervention vs non‐surgical treatment

Quality of life (SRS‐22 Total score) · adolescents with idiopathic scoliosis

1 finding from 1 review

Therapeutic exercises for idiopathic scoliosis in adolescents 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Summary of findings table ‐ Therapeutic exercise plus non‐surgical intervention vs non‐surgical treatment

Cobb angle · adolescents with idiopathic scoliosis

2 findings from 1 review

Therapeutic exercises for idiopathic scoliosis in adolescents 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 84 participants
Low
Therapeutic exercises for idiopathic scoliosis in adolescents 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Summary of findings table ‐ Therapeutic exercise plus non‐surgical intervention vs non‐surgical treatment

Cobb angle ‐ GTE plus other non‐surgical vs non‐surgical · adolescents with idiopathic scoliosis

1 finding from 1 review

Therapeutic exercises for idiopathic scoliosis in adolescents 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Low

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Survival · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 634 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: total score · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 382 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: relative change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
6 participants
GRADE not reported

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

FEV1 % predicted: absolute change from baseline · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 382 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 634 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

OutcomesÂ · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with chemotherapy (low certainty).

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.95 [0.62, 1.47]
2 studies · 331 participants
Low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy (very low certainty).

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
HR 0.88 [0.56, 1.38]
3 studies · 739 participants
Very low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 229 participants
Low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (low certainty).

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.06 [0.8, 1.39]
1 study · 254 participants
Low